Rivaroxaban Inhibits Platelet‐Driven NOX2‐Dependent Oxidative Injury to Endothelium
BACKGROUND: Endothelial dysfunction is a hallmark of cardiovascular disease, driven by oxidative stress, inflammation, and platelet activation. We hypothesized that the FXa inhibitor rivaroxaban, alone or combined with clopidogrel, could counteract platelet-induced oxidative injury to the endothelium and preserve endothelial function. METHODS: We conducted a prospective multicenter cohort clinical study in patients on chronic antiplatelet therapy (mostly aspirin) who initiated rivaroxaban, measuring indices of oxidative stress, endothelial function (nitric oxide bioavailability, ICAM-1/VCAM-1 levels), and platelet activation before and after rivaroxaban. In parallel, human endothelial cells were exposed to convulxin-activated platelet supernatants from healthy donors with or without rivaroxaban±clopidogrel, and assessed for NOX2 expression/activity, adhesion molecules, nitric oxide (NO) production, and tube-forming capacity. An ex vivo mouse model of angiotensin II-induced endothelial dysfunction was used to evaluate vascular relaxation responses after incubation with rivaroxaban and/or clopidogrel. RESULTS: production, downregulated endothelial NOX2 expression and sNOX2-dp release, and restored angiogenic capacity in endothelial cells exposed to activated platelets. Clopidogrel alone had negligible effects on these parameters. Notably, adding clopidogrel to rivaroxaban provided no additional endothelial benefit beyond rivaroxaban monotherapy. In an ex vivo hypertensive vessel model, rivaroxaban (but not clopidogrel) markedly improved endothelium-dependent relaxation. CONCLUSIONS: Rivaroxaban effectively preserves endothelial function by inhibiting platelet-induced NOX2-mediated oxidative stress and inflammation. The lack of any additive benefit from clopidogrel suggests that rivaroxaban alone may be mechanistically sufficient to counteract platelet-driven endothelial dysfunction. These findings reveal a novel vasoprotective mechanism for rivaroxaban and underscore its potential clinical value in mitigating vascular injury beyond its established antithrombotic effects.
Authors
- Silvano Garibaldi (ORCID: https://orcid.org/0000-0003-1279-5050)
- Pasquale Pignatelli (ORCID: https://orcid.org/0000-0002-2265-7455)
- Flavio Di Nonno (ORCID: https://orcid.org/0000-0003-1084-2490)
- Antonio Sili Scavalli (ORCID: https://orcid.org/0000-0003-2534-4224)
- Giovanni Enrico Casciaro (ORCID: https://orcid.org/0000-0002-9464-5461)
- Pietro Ameri (ORCID: https://orcid.org/0000-0001-7167-7287)
- Emanuele Valeriani (ORCID: https://orcid.org/0000-0001-9729-3214)
- Maurizio Forte (ORCID: https://orcid.org/0000-0003-0739-0534)
- Rossella Marcucci (ORCID: https://orcid.org/0000-0001-9549-7176)
- Giulia Ciarrocca Taranta (ORCID: https://orcid.org/0000-0003-4339-652X)
- Alessandra D’Amico (ORCID: https://orcid.org/0000-0002-5571-4583)
- Roberto Carnevale (ORCID: https://orcid.org/0000-0002-6216-9595)
- Ernesto Greco (ORCID: https://orcid.org/0000-0003-3177-5303)
- Vittorio Picchio (ORCID: https://orcid.org/0000-0003-1591-5118)
- Italo Porto (ORCID: https://orcid.org/0000-0002-9854-5046)
- Cristina Nocella (ORCID: https://orcid.org/0000-0003-4398-6327)
- Patrizia Fabbi (ORCID: https://orcid.org/0000-0003-4698-1724)
- Martina Berteotti (ORCID: https://orcid.org/0000-0001-8281-4734)
- Giacomo Frati (ORCID: https://orcid.org/0000-0003-2703-3761)
- Angela Leonardo (ORCID: https://orcid.org/0009-0007-2924-8199)
Institutions
- Istituto Neurologico Mediterraneo (IT)
- European University of Rome (IT)
- Istituto Pasteur (IT)
- IRCCS Azienda Ospedaliera Metropolitana (IT)
- University of Florence (IT)
- University of Genoa (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1161/jaha.126.049175
- Primary Topic
- Nitric Oxide and Endothelin Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00